Thermo Fisher completes $8.9B buyout of Clario

Dive Brief:

Thermo Fisher Scientific said Tuesday that it has closed the $8.9 billion takeover of Clario, expanding its capabilities for handling clinical trial endpoint data.
The buyout, which was announced in October, gives Thermo Fisher a platform for capturing and managing safety data, efficacy results and patient-reported outcomes in clinical trials.
Thermo Fisher will integrate Clario’s platform with its existing capabilities for analyzing biological samples to create a high-growth business, CEO Marc Casper said at a recent investor event.

Dive Insight:

Clario provides regulatory-grade data capture and interpretation technology and services to biopharma companies. Drug developers work with the company to assess the effects of their drug candidates using medical imaging, cardiac safety assessments and tools that capture the views of patients in their trials.

Casper said at a Raymond James event this month that Clario has the best set of technologies for clinical trial endpoints measuring safety, efficacy and patient-reported outcomes. Study sponsors also need to analyze samples from clinical trial participants to show the biological effects of their molecules. Thermo Fisher is the number-two player in clinical trial sample analysis, Casper said.

The CEO said Thermo Fisher will integrate its testing capabilities with Clario’s system to create “a unified endpoint” for clients. Drug developers can use the system in their own trials and in studies they outsource to contract research organizations, including Thermo Fisher’s PPD. Casper said he believes Thermo Fisher will have “the best solution” and create a high-growth business.

In addition to the purchase price, Thermo Fisher will pay Clario $125 million in January 2027, as well as up to $400 million in earn-out payments based on the performance of the business in 2026 and 2027.

Thermo Fisher completed the takeover days after the European Commission approved the acquisition under the EU Merger Regulation. The Commission said the deal will have limited impact on competition, particularly because the combined company will not be able to stop rivals from accessing the market.

The Clario takeover was part of a busy 2025 for Thermo Fisher. The company also struck deals to buy Solventum’s purification and filtration unit for $4.1 billion, and a sterile manufacturing site from Sanofi.